We’ve been covering cytokines and chemokines for several years now before they were hot cakes in the oncology space.
With a raft of new companies emerging in this area to challenge established players, things are getting much more interesting of late. That means it’s time for a new mini series exploring these opportunities through the eyes of the CEOs and CSOs.
We ask what’s different about their approaches and look at why should you be paying attention to them.
We begin with the first of a new three part series exploring novel and intriguing ways to activate cytokines and stimulate the immune system in various cancers.
This story begins with some new Gems from the Poster Halls that readers may well find fascinating…